130 related articles for article (PubMed ID: 37587857)
21. ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
Gonzalez-Bosquet J; Weroha SJ; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Yadav S; Couch FJ; Podratz KC
PLoS One; 2022; 17(12):e0278408. PubMed ID: 36454788
[TBL] [Abstract][Full Text] [Related]
22. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
[TBL] [Abstract][Full Text] [Related]
23.
Liu F; Zou Y; Wang F; Yang B; Zhang Z; Luo Y; Liang M; Zhou J; Huang O
Genet Test Mol Biomarkers; 2019 Jun; 23(6):409-417. PubMed ID: 31161818
[No Abstract] [Full Text] [Related]
24. Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium.
Suda K; Nakaoka H; Yoshihara K; Ishiguro T; Tamura R; Mori Y; Yamawaki K; Adachi S; Takahashi T; Kase H; Tanaka K; Yamamoto T; Motoyama T; Inoue I; Enomoto T
Cell Rep; 2018 Aug; 24(7):1777-1789. PubMed ID: 30110635
[TBL] [Abstract][Full Text] [Related]
25. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Study of Human FBXW7 Deleterious nsSNP's Functional Inference and Susceptibility to Gynaecological Cancer.
Vasuki KA; Christy HJ
Appl Biochem Biotechnol; 2022 Jan; 194(1):407-433. PubMed ID: 34817806
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of FBXW7 loss of function in human cancers.
Fan J; Bellon M; Ju M; Zhao L; Wei M; Fu L; Nicot C
Mol Cancer; 2022 Mar; 21(1):87. PubMed ID: 35346215
[TBL] [Abstract][Full Text] [Related]
29. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
31. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.
Maxwell GL; Risinger JI; Hayes KA; Alvarez AA; Dodge RK; Barrett JC; Berchuck A
Clin Cancer Res; 2000 Aug; 6(8):2999-3005. PubMed ID: 10955777
[TBL] [Abstract][Full Text] [Related]
32. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.
Le Gallo M; O'Hara AJ; Rudd ML; Urick ME; Hansen NF; O'Neil NJ; Price JC; Zhang S; England BM; Godwin AK; Sgroi DC; ; Hieter P; Mullikin JC; Merino MJ; Bell DW
Nat Genet; 2012 Dec; 44(12):1310-5. PubMed ID: 23104009
[TBL] [Abstract][Full Text] [Related]
33. FBXW7 inactivation induces cellular senescence via accumulation of p53.
Gong L; Cui D; Liu D; Shen X; Pan H; Xiong X; Zhao Y
Cell Death Dis; 2022 Sep; 13(9):788. PubMed ID: 36104351
[TBL] [Abstract][Full Text] [Related]
34. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer.
Koul A; Bendahl PO; Borg A; Fernö M; Lidebring MF; Högberg T; Einarsson EL; Ridderheim M; Willén R
Int J Gynecol Cancer; 2002; 12(4):362-71. PubMed ID: 12144684
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
36. STYX/FBXW7 axis participates in the development of endometrial cancer cell via Notch-mTOR signaling pathway.
Liu L; Jiang H; Wang X; Wang X; Zou L
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239181
[TBL] [Abstract][Full Text] [Related]
37. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
38. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Albitar L; Carter MB; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):94-104. PubMed ID: 17490733
[TBL] [Abstract][Full Text] [Related]
39. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
40. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]